Read More 2 minute read News Exelixis and Ipsen Announced Cabozantinib in Combination with an Immune Checkpoint Inhibitor Significantly Improved Progression-Free Survival in Phase 3 COSMIC-312 Pivotal Trial in Patients with Previously Untreated Advanced Liver Cancer By Charles Gross June 28, 5:41 AM Exelixis, Inc. EXEL
